| IELSG50 | Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy |
| Participants required: | 30 |
| Investigator responsible(s): | S. Luminari and W. Zhao |
| Objective(s): | The primary objective of the IELSG50 trial is to test the efficacy of concurrent RT-Pembrolizumab in patients with limited-stage high-risk NK/T cell lymphoma who are not eligible or refuse to receive chemotherapy. |
